LMB-2 immunotoxin

BIOLOGICAL4 trials

Sponsors

National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)

Conditions

LeukemiaLymphomaMelanoma (Skin)Non-melanomatous Skin Cancer

Phase 1

Immunotoxin in Treating Patients With Leukemia or Lymphoma

CompletedNCT00002765

National Cancer Institute (NCI)Leukemia, Lymphoma

Start: 1996-04-30Updated: 2015-04-29

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

CompletedNCT00085150

National Cancer Institute (NCI)Leukemia, Lymphoma

Start: 2004-04-30Target: 40Updated: 2015-04-30

Phase 2

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

CompletedNCT00295958

National Institutes of Health Clinical Center (CC)Melanoma (Skin), Non-melanomatous Skin Cancer

Start: 2005-12-31End: 2008-07-31Updated: 2012-06-14

Unknown Phase

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

WithdrawnNCT00389506

National Institutes of Health Clinical Center (CC)Lymphoma

Start: 2006-09-30End: 2008-05-31Updated: 2012-03-16

Related Papers

Soluble CD22 as a tumor marker for hairy cell leukemia.

2008-07-0224 citations